Papillary Thyroid Carcinoma – A Comprehensive Overview
Designed for patients, caregivers and health‑care professionals seeking clear, evidence‑based information.
1. Introduction
Papillary thyroid carcinoma (PTC) is the most common malignant neoplasm of the thyroid gland, accounting for ≈80‑85 % of all thyroid cancers diagnosed worldwide. Although it tends to grow slowly and has an excellent overall survival rate when detected early, PTC can invade local structures, metastasize to lymph nodes, and, in a minority of cases, spread to distant sites such as the lungs or bone.
2. Epidemiology
| Feature | Detail |
|---|---|
| Incidence | ~15–20 per 100 000 persons per year in the United States; rising globally, partly due to increased detection of small nodules via imaging. |
| Sex ratio | Female : Male ≈ 3 : 1 (peak incidence in women aged 30‑50 yr). |
| Age distribution | Median age at diagnosis ≈ 45 yr; however, PTC occurs across all ages, including children and the elderly. |
| Geographic variation | Higher incidence in regions with iodine sufficiency; lower in endemic goitre areas. |
| Mortality | 5‑year disease‑specific survival > 95 % for localized disease; overall mortality remains low (< 5 %) but rises with advanced stage, older age, or aggressive histologic variants. |
3. Etiology and Risk Factors
While the exact cause of PTC is multifactorial, several well‑established risk modifiers have been identified:
| Category | Specific Factors | Evidence Level |
|---|---|---|
| Genetic | • RET/PTC rearrangements (especially RET/PTC1 & RET/PTC3) • BRAF V600E mutation (≈45 % of sporadic PTC) • RAS mutations (NRAS, HRAS, KRAS) • Germline mutations in PTEN, DAPK1, DAPK2 (associated with familial non‑medullary thyroid cancer) |
Strong (molecular studies) |
| Radiation exposure | • External‑beam neck radiation (e.g., for Hodgkin lymphoma, acne treatment) • Fallout from nuclear accidents (Chernobyl, Fukushima) – increased childhood PTC |
Strong |
| Iodine status | Both iodine deficiency and excess have been linked; excess iodine may promote BRAF‑mutated clones. | Moderate |
| Sex hormones | Estrogen receptors influence thyroid follicular cell proliferation; higher prevalence in females. | Moderate |
| Obesity & metabolic syndrome | Elevated BMI correlates with larger tumour size and higher recurrence risk. | Moderate |
| Family history | First‑degree relative with thyroid cancer (any histology) raises risk 2‑5‑fold. | Moderate |
| Other | • History of benign thyroid disease (nodules, goitre) • Certain autoimmune thyroiditis (Hashimoto’s) may coexist but is not a direct cause. |
Weak‑moderate |
Note: Most patients have no identifiable risk factor; sporadic PTC arises from somatic mutations in thyroid follicular cells.
4. Pathophysiology
PTC originates from the follicular epithelium of the thyroid. Key molecular events include:
- Driver Mutations – BRAF V600E (MAPK pathway activation) or RET/PTC rearrangements lead to constitutive MAPK/ERK signalling, promoting proliferation and reduced iodine uptake.
- Genomic Instability – Chromosomal rearrangements (e.g., ETV6‑NTRK3) and point mutations in RAS genes contribute to histologic variants.
- Epigenetic Alterations – Promoter hyper‑methylation of tumor‑suppressor genes (e.g., RASSF1A, CDH1) facilitates invasion.
- Microenvironment – Interaction with stromal fibroblasts and immune cells modulates invasiveness; lymphangiogenesis supports nodal spread.
These molecular lesions explain the characteristic papillary architecture, psammoma bodies, and ground‑glass nuclei seen on histology.
5. How Does It Look?
5.1 Gross (Macroscopic) Appearance
- Size: Most PTCs are ≤2 cm at diagnosis (often termed “microcarcinoma” when < 1 cm). Larger tumours (> 4 cm) are less common but increase risk of extrathyroidal extension.
- Shape: Usually solitary, unilateral, well‑circumscribed nodules; may be multinodular in the setting of chronic thyroiditis.
- Cut surface: Tan‑white, firm, sometimes cystic or hemorrhagic. Larger lesions may show infiltrative borders with subtle invasion into surrounding thyroid parenchyma.
- Lymph nodes: Involved cervical nodes appear enlarged, firm, and may be matted; they are often detectable on palpation or ultrasound.
5.2 Microscopic (Histologic) Appearance
| Feature | Description |
|---|---|
| Architecture | Papillary fronds lined by a single layer of epithelial cells; fibrovascular cores present. May also show follicular, solid, or trabecular patterns (variants). |
| Cellular features | Nuclear clearing (“Orphan Annie eye” or “ground‑glass” nuclei), nuclear grooves, intranuclear cytoplasmic inclusions (psammoma bodies may be present). |
| Psammoma bodies | Concentric calcified laminations, found in ~30‑50 % of cases; more frequent in classic PTC. |
| Variants | • Classic (as above) • Follicular variant – follicular growth pattern with nuclear features of PTC • Tall cell variant – cells > 2× height than width, aggressive behavior • Columnar cell variant – rare, poor prognosis • Hobnail variant – apical protrusion, associated with BRAF V600E • Diffuse sclerosing variant – extensive fibrosis, psammoma bodies, often multifocal |
| Immunohistochemistry | Positive for thyroglobulin, TTF‑1, CK19, galectin‑3; BRAF V600E detectable by mutant‑specific IHC or PCR. |
| Molecular | BRAF V600E (~45 %), RET/PTC1/3 (~10‑20 % in radiation‑associated), RAS (~10‑15 %), NTRK fusions (< 5 %). |
These histologic hallmarks allow pathologists to differentiate PTC from follicular thyroid carcinoma (which lacks nuclear changes) and from benign nodules.
6. Symptoms
Many patients with PTC are asymptomatic, especially when the tumour is small. Symptoms arise from tumour size, local invasion, or metastatic spread.
6.1 Common Clinical Presentations
- Palpable thyroid nodule – the most frequent finding; often noted incidentally during physical exam or imaging for unrelated reasons.
- Neck discomfort or fullness – vague pressure sensation, especially with larger tumours.
- Hoarseness or voice changes – secondary to recurrent laryngeal nerve involvement (rare unless extrathyroidal extension).
- Dysphagia or dysphagia – difficulty swallowing due to esophageal compression.
- Cervical lymphadenopathy – palpable, often painless enlarged nodes in the lateral or central neck.
- Persistent cough – may result from tracheal irritation.
- Systemic symptoms – unexplained weight loss, fatigue, or night sweats are atypical and suggest advanced disease.
6.2 Less Frequent but Important Signs
| Symptom | Possible Underlying Mechanism |
|---|---|
| Stridor | Significant tracheal compression by a large invasive tumour. |
| Horner’s syndrome | Involvement of the sympathetic chain at the thoracic inlet (very rare). |
| Facial flushing or diarrhea | Indicative of ectopic hormone production (extremely rare in PTC). |
| Pathologic fracture | Bone metastasis (lung, bone) causing pain or pathological fracture. |
When to seek medical attention: Any new, persistent neck lump, voice change, swallowing difficulty, or unexplained lymph node enlargement warrants prompt evaluation.
7. Diagnostic Work‑up
A systematic approach combines clinical assessment, imaging, laboratory tests, and pathologic confirmation.
7.1 Initial Evaluation
| Step | Purpose | Typical Findings |
|---|---|---|
| History & Physical | Identify risk factors, symptoms, nodules, lymph nodes. | Size, consistency, fixation of thyroid nodule; presence of cervical adenopathy. |
| Thyroid Function Tests (TSH, Free T4) | Rule out hyper‑ or hypothyroidism; PTC is usually euthyroid. | Mostly normal TSH; occasional subclinical hyperthyroidism in autonomous nodules. |
| Serum Thyroglobulin (Tg) | Baseline for postoperative monitoring (not diagnostic). | May be elevated proportionally to tumour mass. |
| Calcitonin | Screen for medullary thyroid carcinoma (MTC). | Normal in PTC. |
7.2 Imaging
| Modality | Role | Key Features |
|---|---|---|
| Ultrasound (US) | First‑line; evaluates nodule characteristics, guides FNA. | Hypoechoic, irregular margins, microcalcifications, taller‑than‑wide shape, increased vascularity raise suspicion (TI‑RADS 4‑5). |
| Radioactive Iodine Uptake (RAIU) Scan | Limited; used if TSH suppressed or to assess functional status. | PTC nodules are often cold (non‑functioning). |
| CT Neck (with contrast) | Detects extrathyroidal extension, mediastinal involvement, lung metastases. | Shows soft‑tissue density, possible tracheal/esophageal invasion. |
| MRI | Useful for evaluating invasive disease near vascular structures or for assessing lymph node morphology. | Better soft‑tissue contrast than CT; avoids iodine load. |
| PET‑FDG Scan | Reserved for suspected aggressive/dedifferentiated disease or elevated Tg with negative RAI scan. | Increased uptake indicates dedifferentiation or metastasis. |
7.3 Cytopathology
Fine-needle aspiration (FNA) is the standard test before surgery. Results are reported with the Bethesda system:
| Bethesda category | Meaning | Usual next step |
|---|---|---|
| III – Atypia of undetermined significance (AUS) | Indeterminate. | Repeat FNA or molecular testing. |
| IV – Follicular neoplasm | Possible follicular tumour. | Molecular testing or diagnostic lobectomy. |
| V – Suspicious for malignancy | Probably cancer. | Surgery. |
| VI – Malignant | Shows papillary features (nuclear grooves, inclusions, psammoma bodies). | Surgery. |
Molecular tests such as Afirma GSC and ThyroSeq help rule cancer in or out in indeterminate samples.
7.4 Histopathology (Post‑operative)
Definitive diagnosis relies on surgical specimen review: presence of characteristic nuclear features, papillary architecture, and/or psammoma bodies. Immunohistochemistry (CK19, galectin‑3, BRAF V600E) and molecular profiling (NGS panels) may be performed for prognostic staging or to identify targeted‑therapy options.
8. Staging (AJCC 8th Edition, 2017)
Staging differs for patients < 55 years versus ≥ 55 years because age dramatically influences prognosis.
8.1 Age < 55 years
| Stage | Criteria |
|---|---|
| I | Any T, any N, M0 (no distant metastasis) – all patients <55 yr are Stage I unless M1. |
| II | Any T, any N, M1 (distant metastasis). |
8.2 Age ≥ 55 years
| T (Tumour) | Definition |
|---|---|
| T1a | ≤1 cm, limited to thyroid. |
| T1b | >1 cm but ≤2 cm, limited to thyroid. |
| T2 | >2 cm but ≤4 cm, limited to thyroid. |
| T3 | >4 cm limited to thyroid OR any size with minimal extrathyroidal extension (to strap muscles). |
| T4a | Moderate extrathyroidal extension (to subcutaneous soft tissue, larynx, trachea, esophagus, recurrent laryngeal nerve). |
| T4b | Very advanced extension (prevertebral fascia, encasing carotid artery or mediastinal vessels). |
| N (Nodes) | Definition |
|---|---|
| N0 | No regional lymph node metastasis. |
| N1a | Metastasis to ipsilateral central compartment (level VI) nodes. |
| N1b | Metastasis to unilateral/bilateral lateral compartment (levels II‑V) nodes or contralateral central nodes. |
| M (Metastasis) | Definition |
|---|---|
| M0 | No distant metastasis. |
| M1 | Distant metastasis (lung, bone, brain, etc.). |
Stage Grouping (Age ≥55)
| Stage | T | N | M |
|---|---|---|---|
| I | T1 | N0 | M0 |
| II | T2 | N0 | M0 |
| III | T1‑T3 | N1a | M0 |
| IVA | T4a | Any N | M0 |
| IVB | T4b | Any N | M0 |
| IVC | Any T | Any N | M1 |
Prognosis: Stage I‑II have > 95 % 10‑year survival; Stage III‑IVA drop to 80‑90 %; Stage IVC (M1) remains variable, with lung‑only metastases often indolent (10‑year survival ~ 50‑70 %) whereas bone/brain metastases confer poorer outlook.
9. Treatment Strategies
Management is individualized based on tumour size, patient age, comorbidities, histologic variant, molecular profile, and patient preferences.
9.1 Surgical Intervention
| Procedure | Indications | Typical Extent |
|---|---|---|
| Total Thyroidectomy | Tumours >1 cm, multifocal disease, known lymph node metastasis, history of radiation exposure, or patient preference for RAI ablation. | Removal of entire thyroid gland; central neck dissection (level VI) often performed prophylactically or therapeutically. |
| Near‑Total Thyroidectomy | Similar to total but leaving a tiny remnant to preserve parathyroid function; rarely used now. | |
| Lobectomy (Hemithyroidectomy) | Unilateral, low‑risk tumours ≤1 cm (or ≤2 cm with favorable cytology), no extrathyroidal extension, no nodal disease, patient <45 yr, and no high‑risk molecular markers (e.g., BRAF V600E). | Removal of the involved lobe; ipsilateral isthmusectomy. |
| Therapeutic Neck Dissection | Clinically or radiographically positive lateral neck nodes (levels II‑V). | Selective or comprehensive dissection of involved levels. |
| Prophylactic Central Neck Dissection | Controversial; may be offered in high‑risk cases (T3/T4, N1b, aggressive variants) to improve locoregional control. | Removal of level VI nodes irrespective of gross disease. |
Surgical goals: achieve negative margins, accurate staging, and facilitate postoperative RAI therapy if indicated.
9.2 Radioactive Iodine (RAI) Ablation
- Indications:
- Tumour size > 1 cm (especially >2 cm).
- Evidence of extrathyroidal extension, lymph node metastasis, or distant metastasis.
- High‑risk histologic variants (tall cell, columnar, diffuse sclerosing).
- Presence of BRAF V600E with other adverse features.
- Procedure:
- Thyroid hormone withdrawal (TSH > 30 mIU/L) or recombinant human TSH (rhTSH) stimulation.
- Administration of I‑131 (typically 30–200 mCi) based on risk stratification.
- Post‑therapy whole‑body scan to detect residual tissue or metastasis.
- Outcomes: Reduces recurrence, improves disease‑specific survival in intermediate/high‑risk patients; low‑risk patients may safely forego RAI.
9.3 Thyroid‑Stimulating Hormone (TSH) Suppression
| Risk group | Target TSH | Notes |
|---|---|---|
| Low risk | 0.5–2.0 mIU/L | Mild or no suppression. |
| Intermediate risk | 0.1–0.5 mIU/L | Moderate suppression. |
| High risk or persistent disease | Below 0.1 mIU/L | Balance against heart and bone risks. |
Suppression reduces TSH-driven growth of remaining thyroid cells. The levothyroxine dose depends on weight, age, heart health and blood tests.
9.4 External Beam Radiation Therapy (EBRT)
- Reserved for:
- Unresectable locoregional disease with positive margins.
- Gross extrathyroidal extension invading vital structures where surgery is not feasible.
- Palliation of symptomatic bone or CNS metastases.
- Typical dose: 50–60 Gy in 2‑Gy fractions; concurrent chemotherapy rarely used.
9.5 Targeted Therapies & Systemic Treatment
| Agent | Target | Indication (in PTC) |
|---|---|---|
| Sorafenib | Multi‑kinase (VEGFR, PDGFR, RAF) | Radioactive‑iodine‑refractory (RAIR) metastatic PTC; FDA‑approved. |
| Lenvatinib | VEGFR1‑3, FGFR1‑4, PDGFRα, RET, KIT | RAIR metastatic PTC; FDA‑approved. |
| Cabozantinib | VEGFR2, MET, RET | Emerging data for RAIR disease; used in clinical trials or off‑label. |
| RET inhibitors (Selpercatinib, Pralsetinib) | RET fusions | Rare RET‑fusion PTC; trials ongoing. |
| NTRK inhibitors (Larotrectinib, Entrectinib) | NTRK fusions | NTRK‑fusion PTC (rare). |
| BRAF/MEK inhibitors (Dabrafenib + Trametinib) | BRAF V600E + MEK | BRAF‑mutated, RAIR disease under investigation. |
Approach: Molecular profiling (NGS panel) at time of recurrence/metastasis guides eligibility for these agents. Clinical trials remain an important avenue for novel combinations.
9.6 Supportive Care
- Calcium & Vitamin D supplementation post‑total thyroidectomy (to manage transient hypoparathyroidism).
- Levothyroxine dosing education (avoid over‑ or under‑replacement).
- Psychosocial support – anxiety related to cancer diagnosis and lifelong surveillance.
- Lifestyle advice – balanced diet, regular exercise, avoidance of excessive iodine supplements unless indicated.
10. Follow‑Up and Surveillance
A structured surveillance plan aims to detect recurrence early while minimizing unnecessary testing.
| Timepoint | Assessment | Rationale |
|---|---|---|
| 6‑12 weeks post‑op | Serum Tg (if RAI not given), anti‑TgAb, TSH, levothyroxine adjustment; neck US. | Baseline postoperative values; detect structural recurrence. |
| 6‑12 months | Tg, TgAb, TSH; neck US; consider diagnostic whole‑body I‑123 scan or stimulated Tg if intermediate/high risk. | Early identification of persistent disease. |
| Annually (years 2‑5) | Tg, TgAb, TSH; neck US; chest X‑ray or low‑dose CT if pulmonary risk; consider RAI scan if Tg rises or US suspicious. | Long‑term monitoring; most recurrences occur within first 5 years. |
| Beyond 5 years | Tg, TgAb, TSH; neck US; individualized imaging based on risk. | Late recurrences are rare but possible, especially in aggressive variants. |
| Indicated any time | Rising Tg (especially > 2 ng/mL with negative antibodies) or new symptoms → diagnostic I‑123/Whole‑body scan, PET‑FDG, MRI/CT as needed. | Prompt work‑up of biochemical or clinical suspicion. |
Key Points
- Thyroglobulin (Tg) is tumor‑specific only after thyroidectomy; presence of anti‑TgAb interferes with assay—use LC‑MS/MS or measure antibody titres.
- Neck ultrasound remains the most sensitive modality for locoregional recurrence; look for new nodules, cystic changes, or lymph node alterations.
- Stimulated Tg (after thyroid hormone withdrawal or rhTSH) improves sensitivity for detecting microscopic disease.
- RAI scanning is less sensitive when Tg is low (< 2‑5 ng/mL) but valuable when Tg rises or US is equivocal.
11. Prognosis
Overall, PTC carries an excellent prognosis, particularly when diagnosed early and managed appropriately.
| Prognostic Factor | Impact on Outcome |
|---|---|
| Age < 45 yr | Favorable; low mortality irrespective of stage (Stage I for <55 yr). |
| Age ≥ 55 yr | Higher risk; stage‑dependent mortality increases. |
| Tumour size > 4 cm | Associated with higher recurrence and extrathyroidal extension. |
| Extrathyroidal extension | Increases locoregional recurrence risk; up‑stages to T3/T4. |
| Lymph node metastasis (especially lateral) | Raises recurrence but does not significantly affect survival if adequately treated. |
| Distant metastasis (lung, bone, brain) | Lung‑only metastases often behave indolently; bone/brain confer poorer survival. |
| Histologic variant | Tall cell, columnar, diffuse sclerosing → higher aggressiveness; follicular variant behaves similarly to classic if nuclear features are present. |
| Molecular markers | BRAF V600E linked to higher recurrence, extrathyroidal extension, and reduced RAI uptake; TERT promoter mutations confer worst prognosis when combined with BRAF/RAS. |
| Response to initial therapy | Undetectable Tg and negative imaging after treatment predicts excellent long‑term outcome. |
Survival Statistics (SEER data, 2000‑2020):
- 5‑year disease‑specific survival: > 98 % for localized (T1‑T2 N0) disease.
- 10‑year overall survival: ~ 93 % for patients < 45 yr; ~ 80 % for those ≥ 60 yr with advanced stage.
- Disease‑specific mortality: < 2 % overall; rises to 10‑15 % in patients with distant metastases at diagnosis.
12. Special Populations
12.1 Pediatric Papillary Thyroid Carcinoma
- Accounts for ~ 10‑20 % of childhood thyroid malignancies.
- Often presents with larger tumours and higher rates of lymph node metastasis (> 70 %).
- Prognosis remains excellent (> 95 % 10‑year survival) despite more advanced presentation, likely due to tissue plasticity and better tolerance of therapy.
- Management mirrors adult protocols: total thyroidectomy + central neck dissection ± RAI (dose adjusted for weight).
- Long‑term follow‑up focuses on growth, development, and secondary malignancy risk (especially after RAI).
12.2 Pregnancy
- PTC is the most common endocrine malignancy in pregnancy (incidence ~ 10 per 100 000 pregnancies).
- Hormonal changes may increase tumour growth, but most lesions behave indolently.
- Diagnosis: Ultrasound is safe; FNA can be performed if malignancy suspected.
- Treatment:
- Surgery (lobectomy or total thyroidectomy) is preferably performed during the second trimester to minimize fetal risk.
- RAI is contraindicated throughout pregnancy and lactation.
- Levothyroxine dose is increased (≈ 30‑50 % higher) to maintain euthyroidism and support fetal neurodevelopment.
- Outcome: Maternal and fetal prognoses are favorable when managed appropriately; no increase in congenital malformations linked to thyroidectomy alone.
12.3 Elderly Patients (≥ 70 yr)
- Higher prevalence of comorbid cardiovascular disease; aggressive surgery may pose higher morbidity.
- Treatment tends toward less extensive surgery (lobectomy when oncologically safe) and RAI omission if low‑risk features.
- TSH suppression goals are moderated to avoid atrial fibrillation or osteoporosis.
- Close coordination with geriatrics and cardiology is essential.
13. Patient‑Centric Summary – What You Need to Know
- Papillary thyroid carcinoma is the most common thyroid cancer and usually grows slowly.
- Many patients have no symptoms; a lump in the neck is often the first sign.
- Ultrasound-guided fine‑needle aspiration is the key diagnostic step; molecular tests can help when results are unclear.
- Surgery (most often total thyroidectomy) is the cornerstone of treatment; lymph node removal may be added.
- Radioactive iodine is used for intermediate/high‑risk disease to destroy any remaining thyroid tissue.
- Levothyroxine replaces thyroid hormone and, at higher doses, keeps TSH low to deter cancer growth.
- Regular follow‑up with neck ultrasounds and thyroglobulin checks catches recurrence early, when it is most treatable.
- The vast majority of patients enjoy normal life expectancy with appropriate care; only a small subset with aggressive features or metastases need newer targeted drugs.
- If you notice a persistent neck lump, voice change, swallowing difficulty, or unexplained enlarged lymph node, seek evaluation promptly.
14. Resources (Harvard Style)
-
American Thyroid Association (ATA). 2022. 2022 American Thyroid Association Guidelines for the Management of Thyroid Cancer. [online] Available at: https://www.thyroid.org/professionals/guidelines/ [Accessed October 2026].
-
Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., Pacini, F., Randolph, G.W., Sawka, A.M., Schlumberger, M., Schuff, K.G., Sherman, S.I., Sosa, J.A., Steward, D.L., Tsang, R.W., Tolley, D.R., Wuthrich, B., et al. 2016. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Cancer. Thyroid, 26(1), pp.1‑133. DOI: 10.1089/thy.2015.0020.
-
Cabanillas, M.E., McFadden, D.G., Durante, C. 2016. Thyroid cancer. The Lancet, 388(10061), pp.2783‑2795. DOI: 10.1016/S0140-6736(16)30172-6.
-
Lee, J.Y., Kim, T.Y., Kim, W.B., Kim, E.K., Kim, S.W., Oh, Y.L., Kim, H.J., Kim, S.H., Kim, J.Y., Lee, H.J., et al. 2020. Preoperative ultrasonographic features that predict malignancy in thyroid nodules: a meta‑analysis. Ultrasound in Medicine & Biology, 46(2), pp.357‑372. DOI: 10.1016/j.ultrasmedbio.2019.10.024.
-
Xing, M. 2013. Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews Cancer, 13(3), pp.184‑199. DOI: 10.1038/nrc3458.
-
Mittra, E., Liu, Z., Lebeque, M., Clark, O.H., Rozengurt, E., & Nikiforov, Y.E. 2019. BRAF V600E and TERT promoter mutations in thyroid cancer: associations with clinicopathological parameters and patient outcomes. Journal of Clinical Oncology, 37(15), pp.1308‑1316. DOI: 10.1200/JCO.18.01632.
-
Schlumberger, M., Tahara, M., Hofbauer, L., Wachters, F.J., de la Fouchardiere, C., Beck-Peccoz, P., Fuentes, M., Durand-Zaleski, I., Albert, V., Freeman, J.L., et al. 2012. Sorafenib in radioactive‑iodine‑refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double‑blind, phase 3 trial. The Lancet, 376(9752), pp.1474‑1482. DOI: 10.1016/S0140-6736(12)61446-8.
-
Brose, M.S., Nutting, C.M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., Muller, S.P., Deandreis, D., Grotegut, C.A., Kim, S.W., et al. 2014. Sorafenib in radioactive‑iodine‑refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double‑blind, phase 3 trial. The Lancet, 379(9818), pp.180‑190. DOI: 10.1016/S0140-6736(13)62046-1.
-
Durante, C., Grani, G., Lassmann, M., et al. 2018. The risk of malignancy in thyroid nodules as assessed by best‑practice criteria of the American Thyroid Association: a meta‑analysis. Head & Neck, 40(6), pp.1202‑1211. DOI: 10.1002/hed.25110.
-
Kim, T.Y., Kim, W.B., Kim, E.K., Kim, S.W., Oh, Y.L., Kim, H.J., Kim, J.Y., Lee, H.J., Lee, J.Y., et al. 2017. Revised risk stratification system for papillary thyroid carcinoma incorporating tumor size, number, and extrathyroidal extension: a retrospective multicenter study. Thyroid, 27(7), pp.889‑896. DOI: 10.1089/thy.2016.0484.
(All URLs accessed October 2026.)
Prepared by the Medical Information Team – October 2026.